Overview of HIV Prevention

  • Author: Sharon L. Hillier, PhD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 8/24/18 (What's New)

Summary

  • The use of topical tenofovir gel evaluated as PrEP in HIV-uninfected women
    • CAPRISA 004 study found that tenofovir 1% gel reduced HIV acquisition by 39% overall and by 54% among women with adherence > 80%[Abdool Karim 2010]
    • VOICE and FACTS-001 trials found that topical tenofovir had no protective effect against HIV infection[Marrazzo 2015; Rees 2015]

Action required